Alibaba Health Reports 22.9% Revenue Growth in H1 2022
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...
3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...
China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau
China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...
Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo
The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...
Huadong Medicine Partners with Dongyang Med for Equity Collaboration
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...
Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development
Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...
Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...
China Resources Double-Crane Gains Approval for Definity in China
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...
XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...